Dose and Side Effects: Three Labels Publish the Gradient, and Neither Weight Label Does

Every GLP-1 starts low and climbs. Every label gives the same reason for it, and it is not effectiveness — the escalation exists to limit adverse reactions. All twelve approved schedules, and the shared wording behind them, are collected on our titration schedules page.

That raises an obvious question the schedules themselves never answer: how much difference does the dose actually make? This page answers it from the only documents that can, which are the approved labels' own placebo-controlled tables, and the first finding is about which labels those are.

Only three labels publish the gradient, and none of them is a weight-loss label

Of the current US GLP-1 labels, three report adverse reactions broken down by dose:

• TRULICITY (dulaglutide), 0.75 mg and 1.5 mg against placebo
• The semaglutide tablets, 7 mg and 14 mg against placebo — the same table appears on both the OZEMPIC and RYBELSUS labels
• VICTOZA (liraglutide), 1.2 mg and 1.8 mg against placebo

All three are diabetes labels.

The two weight-management labels read for this page do not stratify at all. WEGOVY's pooled table reports one column, WEGOVY 2.4 mg against placebo. SAXENDA's reports one column, SAXENDA against placebo. Both are maintenance-dose figures.

So the indication in which titration is most discussed, most extended and most often stalled is the one for which no approved document publishes a dose-by-dose adverse reaction table. Anyone describing how side effects change while climbing a weight-management schedule is inferring it from diabetes trials of other molecules — which is defensible, but is not what the sentence usually says.

It also explains a limit on our own side effects page, which reports single figures for Wegovy and Zepbound because single figures are all those labels contain. And it is the documentary gap underneath the practice of staying deliberately low, which we cover on GLP-1 microdosing: the tolerability half of that argument has published numbers only for three diabetes products.

What the three tables show

Rates are the percentage of patients reporting the reaction at least once, from each label's placebo-controlled pool.

Subtract the placebo column, and the shape appears

A raw rate mixes the drug's effect with whatever the trial population reports anyway. Subtracting the placebo rate leaves the excess attributable to the drug, and dividing one dose's excess by the other's says whether the reaction scales with dose. Both operations are ours; the labels publish only the raw percentages.

Three things follow.

Where the dose doubles, nausea and vomiting more than double. Dulaglutide's excess vomiting rises 2.81-fold on a 2-fold dose step; nausea on the semaglutide tablets rises 2.80-fold. This is supra-proportional, and it is the quantitative fact behind every label's insistence on a slow climb.

The effect is concentrated in the gut. Outside the gastrointestinal reactions, the only clear step in these three tables is dulaglutide's fatigue. Liraglutide's nasopharyngitis moves 8, 9, 10 and its upper respiratory tract infection 6, 7, 6 — the movement of background illness in a trial population, not of a drug effect.

And it is not universal. Liraglutide's 1.5-fold step lifts excess nausea by only 15%, far less than the dose. Whether that is a property of the molecule, of its daily schedule, or of the fact that both arms are already well past the threshold where nausea appears, these tables cannot say.

Three reactions that go the wrong way

The most informative rows in the set are the ones that fall.

• Constipation, semaglutide tablets: 2% placebo, 6% at 7 mg, 5% at 14 mg.
• Decreased appetite, VICTOZA: 1% placebo, 10% at 1.2 mg, 9% at 1.8 mg.
• Headache, VICTOZA: 7% placebo, 11% at 1.2 mg, 10% at 1.8 mg.

Each of these is well above placebo at both doses, so the drug is doing something. But none rises with the dose, and one of them is decreased appetite — the effect the drug is taken for, showing no gradient across a 50% dose increase in this pool.

Single percentage points in tables of a few hundred patients are inside the noise, and none of these differences should be read as a real decline. Read correctly they say something more useful: a reaction that does not track the dose is not being driven by the dose. That is a different kind of fact from a rate, and it is invisible unless the label publishes both columns — which, for the weight-management products, none of them does.

What this page does not establish

These are three molecules, two doses each, from placebo-controlled pools in populations with type 2 diabetes, and adverse reaction rates from one drug's trials cannot be compared with another's. Nothing here transfers to a weight-management product, to a dose outside the pairs tabulated, or to any individual.

The excess-over-placebo figures and the factors are arithmetic on published percentages, not a reanalysis of patient data; they carry no confidence intervals, because the labels publish none, and they should be read as the shape of a relationship rather than as estimates.

Nothing on this page is guidance about what dose anyone should be on. That decision belongs to the prescriber who wrote the prescription, and our editorial standards explain why we leave it there.

Sources and dates

• TRULICITY prescribing information, Table 1, adverse reactions in the placebo-controlled pool, SPL effective 2023-08-05 — read 2026-09-21 via openFDA.
• OZEMPIC and RYBELSUS prescribing information, semaglutide tablets adverse reaction table, SPL effective 2026-01-30 — read 2026-09-21 via openFDA.
• VICTOZA prescribing information, adverse reactions in placebo-controlled trials, SPL effective 2023-02-06 — read 2026-09-21 via openFDA.
• WEGOVY prescribing information, SPL effective 2024-04-23, and SAXENDA prescribing information, SPL effective 2026-02-25 — read 2026-09-21 via openFDA, to establish that neither stratifies by dose.